Mendus’s lead asset, vididencel, is fast approaching the pivotal stages of development in acute myel...
Smart Eye has announced an agreement to license iris recognition technology from Fingerprint Cards f...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) offentliggjorde den 31 december...
Redeye comments on announcing a new pilot involving the renowned Mayo Clinic.
Redeye adjusts its estimates after Institut Bergonié terminated the collaboration agreement to explo...
Redeye provides a comment on today's news in Scandinavian ChemoTech regarding the separation of Huma...
IT market weakness hitting Proact After showing good resilience so far this year, Proact had to prof...
Tangiamo Touch Technology (”Tangiamo” eller ”bolaget”) meddelade den 19 december 2024 att bolaget ha...
Redeye comments on Maximum Entertainment’s divestment of certain assets within Merge Games which wil...
Redeye provides a brief comment on Mendus announcing that Institut Bergonié terminated the collabora...
Gapwaves entered a product sales agreement with Smartmicro worth SEK90m, with an expected ramp-up st...
Redeye comments on the recent funding by Smart Eye’s main competitor, Seeing Machines, which has ent...
Redeye comments briefly on Evolution’s press release regarding a review initiated by UKGC due to Evo...
Redeye comments on Freemelt’s plan to resolve a SEK100m rights issue, with 90% secured through subsc...
Redeye comments on Gasporox’s convertible debt financing.
Accenture Q1'25 grew 8% (+3% vs cons), driven by a broad base Raises FY guidance from 3-6% growth to...
Imflifidase shows robust efficacy results in phase 2 among patients with severe GBS.
On December 18th, STENOCARE announced that the company has resolved a rights issue of up to DKK 20.
Avtech has secured its second-largest contract, signing an agreement with LATAM Airlines valued at E...
Enersense's wind power development portfolio has been divested, and losses from non-core operations ...
